ROCKVILLE, Md., Feb. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BIO CEO and Investor Conference, to be held at the Waldorf-Astoria Hotel, February 12-14, 2007. Mr. Burns’ presentation is scheduled for Tuesday, February 13, 2007 at 2:15 p.m. (local time).
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
Mr. Burns’ live presentation will be web cast and can be accessed through the Company’s web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.
About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
CONTACT: Ginny Dunn Associate Director Corporate Communications & Investor Relations EntreMed, Inc. 240-864-2643
Photo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comEntreMed, Inc.
CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643
Web site: http://www.entremed.com/
